Bulk Versus Fractionated Stem Cell Infusions in Patients With Hematologic Malignancies Undergoing Stem Cell Transplantation

Leukemia Clinical Trial

Official title:

Randomized Phase II Trial of Bulk Versus Fractionated Stem Cell Infusions in Patients With Hematologic Malignancies Undergoing Stem Cell Transplantation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01596257
• Other study ID #: 12-016
• Status: Completed
• Phase: Phase 2
• Start date: May 5, 2012
• Est. completion date: August 30, 2021

Study information

• Verified date: August 2021
• Source: Memorial Sloan Kettering Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to find out if getting a blood stem cell transplant with donor stem cells given over several days is better than getting a blood stem cell transplant with donor stem cells given over 1 day. We want to find out which procedure over will result in improved recovery of blood and immune function after transplant. When donor stem cells are given over various days in mice, the blood and immune system recovery is quicker.

Description:

This is a complex study that involves various interventions, Intervention #1: Donor Initial Stem Cell Collection; Intervention #2: Stem Cell Product Initial Processing Orders; Intervention #3 Patient Admission and Transplantation; Intervention #4: Stem cell infusion; Intervention #5: Post infusion follow up; Intervention #6: Off Study Patient and Donor Evaluation. Patients whose donor fails to collect the appropriate number of cells will receive all their cells as a bulk infusion. These patients will continue to receive a transplant on protocol but will be replaced until both arms have reached the target accrual.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 116
• Est. completion date: August 30, 2021
• Est. primary completion date: August 30, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A to 75 Years

Eligibility

Inclusion Criteria:

• Patients who are considered candidates for an allogeneic stem cell transplantation as

treatment for any of the following hematologic disorders:

• Acute Leukemia
• Myelodysplastic syndrome
• Other myeloproliferative disorder (i.e. myelofibrosis, chronic myelomonocytic leukemia, or chronic myelogenous leukemia)
• Non Hodgkins Lymphoma
• Hodgkins Disease
• Multiple Myeloma
• Age includes from birth to < 75 years old.
• Patients must have a Karnofsky (adult) or Lansky (pediatric) Performance Status > 70%
• Patients must have adequate organ function measured by:
• Cardiac: asymptomatic or if symptomatic then LVEF at rest must be > 40%
• Hepatic: < 5x ULN ALT and < 1.5 total serum bilirubin, unless there is congenital benign hyperbilirubinemia.
• Renal: serum creatinine <1.5 mg/dl or if serum creatinine is outside the normal range, then CrCl > 40 ml/min (measured or calculated/estimated)
• Pulmonary: asymptomatic or if symptomatic, DLCO > 40% of predicted (corrected for hemoglobin).

Exclusion Criteria:

• Female patients who are pregnant or breast-feeding.
• Active viral, bacterial or fungal infection
• Patient seropositive for HIV-I/II; HTLV -I/II
• Presence of leukemia in the CNS
• Candidate for a protocol of higher priority. For the purpose of this study, the following protocols will be considered of higher priority: 10-051

Donor Inclusion Criteria:

• HLA compatible related or unrelated donor, (i.e. a fully matched unmanipulated grafts or 1-2 HLA allele disparate donor for CD34 selected grafts).
• Meets criteria outlined in the FACT-approved SOP for "DONOR EVALUATION AND SELECTION FOR ALLOGENEIC TRANSPLANTATION" in the Blood and Marrow Transplant Program Manual, document E-1 see http://mskweb5.mskcc.org/intranet/html/80312.cfm
• Donor must have adequate peripheral venous catheter access for leukapheresis or must agree to placement of a central catheter.
• Wt >25kg

Donor Exclusion Criteria:

• Evidence of active infection (including urinary tract infection, or upper respiratory tract Infection) or viral hepatitis exposure (on screening), unless only HBS Ab+ and HBV DNA negative.
• Medical or physical reason which makes the donor unlikely to tolerate or cooperate with growth factor therapy and leukapheresis.
• Factors which place the donor at increased risk for complications from leukapheresis or GCSF therapy (e.g., autoimmune disease, sickle cell trait, symptomatic coronary artery disease requiring therapy).
• Pregnancy (positive serum or urine ß-HCG) or breastfeeding. Women of childbearing age must avoid becoming pregnant while on the study

Related Conditions & MeSH terms

• Hematologic Neoplasms
• Leukemia

Intervention

Procedure:
• allogeneic hematopoietic stem cell transplantation
Undergo allogeneic hematopoietic stem cell transplant

Device:
• CliniMACS

Locations

Country	Name	City	State
United States	Memorial Sloan Kettering Cancer Center	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
Memorial Sloan Kettering Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Median Time to Engraftment of Neutrophils	Determine the effects of fractionated vs. bulk stem cell infusions on neutrophil recovery as defined by number of days with an absolute neutrophil count of less than 500 neutrophils per micro liter and time to an absolute neutrophil count (ANC) of 500. Determing the median time to ANC of >/= 0.5 x 10^9/L	Up to 100 weeks
Secondary	Number of Participants Assessed for Toxicities	Participants will be assessed for toxicities with the NCI-Common Terminology for Adverse Events (CTCAE), version 4.0.	2 years
Secondary	Median Time to Platelet Engraftment	The area under the hematopoietic recovery curve for the factors: ALC, CD4, CD8, and platelet count. The area under the curve will be computed based on recordings at days 30, 60, 100, 180, 365. Determine days to platelet engraftment by platelet count.	Up to 365 days
Secondary	Overall Survival	Percentage of participants alive at 24 months	24 months
Secondary	Hematopoietic Function on Day 30	Determine the difference of CD4+ lymphocyte recovery between the two arms on day 30	30 days
Secondary	Hematopoietic Function on Day 180	Determine the difference of CD4+ lymphocyte recovery between the two arms on day 180	180 days
Secondary	Hematopoietic Function on Day 360	Determine the difference of CD4+ lymphocyte recovery between the two arms on day 360	360 days

External Links

•   Memorial Sloan Kettering Cancer Center